Skip to main content
ZJAMP Group Co., Ltd. logo

ZJAMP Group Co., Ltd. — Investor Relations & Filings

Ticker · 002758 ISIN · CNE100002029 LEI · 3003009OKT32LB5C0T64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,563 across all filing types
Latest filing 2019-09-02 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002758

About ZJAMP Group Co., Ltd.

https://www.znjtgf.com

ZJAMP Group Co., Ltd. specializes in the comprehensive distribution and supply chain management of agricultural production materials. The company’s core operations encompass the procurement, storage, and sale of essential inputs, including chemical fertilizers such as urea, potash, and compound fertilizers, as well as pesticides, seeds, and agricultural machinery. Beyond product distribution, the organization provides integrated technical services, modern logistics solutions, and agricultural consultancy to enhance crop yields and farming efficiency. By leveraging an extensive network of distribution centers and service stations, the group facilitates the stable supply of high-quality agricultural resources. Its business model focuses on bridging the gap between manufacturers and end-users through efficient resource allocation and value-added services.

Recent filings

Filing Released Lang Actions
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report". It details a significant change in shareholding and control of Zhejiang Huatong Pharmaceutical Co., Ltd., including the transfer of shares, changes in actual control, and related agreements. The document includes detailed information about the parties involved, share transfer agreements, payment terms, and management changes related to the equity transfer. This type of document corresponds to a notification of changes in major shareholding levels or control of the company. It is not an annual report, earnings release, or management report, but specifically a report on a significant shareholding change. Therefore, the appropriate classification is "Major Shareholding Notification" (Code: MRQ). The document length and detail confirm it is the report itself, not just an announcement or a brief notice.
2019-09-02 Chinese
关于控股股东股权结构变动暨实际控制人变更的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a detailed announcement regarding a change in the equity structure of the controlling shareholder and the change of the actual controller of Zhejiang Huatong Pharmaceutical Co., Ltd. It includes extensive information about the share transfer agreement, parties involved, shareholding percentages, payment terms, management changes, and related legal and procedural details. The document is not a financial report, earnings release, or audit report. It is not a simple announcement of voting results or a proxy statement. Instead, it is a regulatory announcement about a significant change in major shareholding and control of the company, involving a transfer of 57% of shares of the controlling shareholder. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is lengthy and detailed, not a brief announcement or a report publication notice. Therefore, the appropriate classification is MRQ with high confidence.
2019-09-01 Chinese
2019年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '浙江华通医药股份有限公司 2019 年半年度财务报告' which translates to 'Zhejiang Huatong Pharmaceutical Co., Ltd. 2019 Half-Year Financial Report'. It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2019. The document explicitly states it is a '半年度财务报告' (half-year financial report) and includes comprehensive financial data and analysis for the period. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-08-28 Chinese
关于2019年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the storage and usage of funds raised in the first half of 2019. It includes specifics about the amounts raised from initial public offerings and convertible bonds, the management and storage of these funds in special accounts, usage details, project progress, changes in project implementation, and compliance with regulatory requirements. The document references regulatory approvals, audit verification reports, and shareholder meeting approvals related to fund usage. The content focuses exclusively on the management and use of raised capital, including detailed tables and explanations of fund allocation and project status. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is substantive and not merely an announcement or certification, so it is not classified as RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2019-08-28 Chinese
独立董事关于公司第三届董事会第二十二次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion statement from the independent directors of Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the company's 2019 half-year fundraising fund usage, external guarantees, related party fund occupation, and accounting policy changes. It references regulatory compliance with the China Securities Regulatory Commission and Shenzhen Stock Exchange rules. The document is relatively short (965 characters) and does not contain detailed financial statements or comprehensive financial data. It is a formal opinion related to governance and compliance matters rather than a full financial report or audit report. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2019-08-28 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding a change in accounting policies. It details the reasons for the change, the specific changes in accounting policies, and includes approvals from the board of directors, supervisory board, and independent directors. The document does not contain actual financial statements or detailed financial data but rather informs stakeholders about the policy change and its compliance with regulatory requirements. The document length is 2290 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about accounting policy changes without substantive financial data or a full report attached.
2019-08-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.